NEW DIRECTIONS IN SMALL-VESSEL VASCULITIS: ANCA, TARGET ORGANS, TREATMENT, AND BEYOND

PROCEEDINGS OF A SYMPOSIUM

Supplement 3 to Volume 79 • November 2012

www.ccjm.org/content/79/Suppl_3

Contents

Diagnosis, ANCA testing, and disease activity
Clinical features and diagnosis of small-vessel vasculitis.......................... S3
Carol Langford, MD, MHS

Controversies in ANCA testing ........................................ S7
Ulrich Specks, MD

Defining disease activity and damage in patients with small-vessel vasculitis........ S11
Peter A. Merkel, MD, MPH

Impact on individual organs
Upper airway manifestations of granulomatosis with polyangiitis .............. S16
Daniel S. Alam, MD; Rahul Seth, MD; Raj Sindwani, MD; Erika A. Woodson, MD; and Karrthik Rajasekaran, MD

Renal disease in small-vessel vasculitis .......... S22
Kirsten de Groot, MD

Pulmonary disease in small-vessel vasculitis .... S27
Thomas R. Gildea, MD, MS

Ocular manifestations of small-vessel vasculitis ... S31
James A. Garrity, MD

Monitoring and safety
Monitoring patients with vasculitis ............... S34
Alexandra Villa-Forte, MD, MPH

Safety issues in vasculitis: Infections and immunizations in the immunosuppressed host.... S38
Carlos M. Isada, MD, FCCP

Treatment considerations
Treating vasculitis with conventional immunosuppressive agents......................... S46
David Jayne, MD, FRCP

Biologic agents in the treatment of granulomatosis with polyangiitis ................. S50
Ulrich Specks, MD

Historical perspective
History of vasculitis: The life and work of Adolf Kussmaul ................................. S54
Eric L. Matteson, MD, MPH

Copyright © 2012 The Cleveland Clinic Foundation. All rights reserved.